ACAD positive Adcom vote. OPK receives CRL. PTIE DRRX resubmit NDA + AEZS AMPE ARLZ AUPH BLRX CBAY CLBS CRBP KERX MIRN OHRP RNN VBLT updates

Mar 30, 2016 No Comments by

Updates to the Company Pipeline Database for March 29, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACAD 23.81 Pimavanserin Parkinson’s disease psychosis (PDP) PDUFA PDUFA date May 1 2016 of Pimavanserin for Parkinson’s disease psychosis (PDP) – under priority review. Psychopharmacologic Drugs Advisory Committee Meeting March 29 2016 […]

Daily News Read more

Database updates for ACOR ACRS AEZS CTIX CYTX DCTH EYEG INCY SYN TGTX TRVN ZGNX

Jan 20, 2016 No Comments by

Updates to the Company Pipeline Database from January 19, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACOR 37.55 Tozadenant Parkinson’s disease Phase 3 Announced January 2016 that it entered into an agreement to acquire Biotie Therapies Corp which is currently in Phase 3 development of Tozadenant for Parkinson’s […]

Daily News Read more

AEZS and GALE give pipeline updates. GTXI and ESPR initiate Phase 2 and 3 trials

Jan 14, 2016 No Comments by

Updates to the Company Pipeline Database from January 13, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: AEZS 2.77 Zoptrex Cancer – castration- and taxane-resistant prostate cancer Phase 3 Phase 3 trial to be completed 2H 2016 ESPR 14.11 Bempedoic acid (ETC-1002-040) Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins Phase […]

Daily News Read more

61 pipeline updates for 42 companies from May 7 and 8

May 09, 2015 1 Comment

Latest updates to the Company Pipeline Database for May 7 and 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 9.43 ACH-3422 in combination with ACH-3102 HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks Phase 2 Phase 2 to be initiated 2Q 2015. SVR4 results are expected […]

Read more

Latest calendar updates for AEZS GALE NEOT

Apr 15, 2015 No Comments

Latest updates to the Company Pipeline Database. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AEZS 0.58 Macimorelin Acetate – Macrilen Adult Growth Deficiency CRL CRL Nov 5 2014. Announced mid-April 2015 plans to initiate a Phase 3 trial GALE 1.45 NeuVax (E75) – PRESENT Cancer – low-to-intermediate HER2+ breast […]

Read more

Latest biotech updates for week ended March 20

Mar 22, 2015 No Comments

Latest updates to the Company Pipeline Database for the week ending March 20. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACRX 4.15 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 trial initiated March 2015. Data due 4Q 2015 3/22/2015 ANTH 4.34 Blisibimod Lupus Phase 3 Missed primary endpoints […]

Read more

Upcoming data for CUR KBIO NKTR. AVNR approval delay likely. DVAX reverse split + AEZS RMTI GNCA HRTX IMMU TLOG OPK DSCO ANAC IMMU HPTX SPPI RPTP CMRX VSAR

Nov 08, 2014 No Comments

Neuralstem, Inc. (NYSE MKT: CUR) announced that the Phase 2 data lock of NSI-566 spinal cord-derived stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS) is scheduled to conclude in late January 2015 at which time the company anticipates providing its Phase 2 ALS results. The company also noted that a Phase 2 trial of NSI-189 for […]

Read more

MDCO and NVS Adcom dates set. AEZS raising more cash. Approvals for BMY AZN GSK + updates for MSTX ALKS

Jan 09, 2014 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.46) announced that it has commenced another underwritten public offering of common shares and warrants, their third offering in just over five months. GW Pharmaceuticals plc (Nasdaq: GWPH $38.06) announced the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the NASDAQ Global Market. GW will issue 2,441,110 ADSs […]

Read more

AEZS PDUFA date set. NBIX meets endpoint. PSTI Ph 1/2 PLX-PAD next week + RCPT GNBT GEVA

Jan 07, 2014 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS)  announced that the FDA has assigned a PDUFA date of November 5, 2014 for Macimorelin Acetate in patients with Adult Growth Hormone Deficiency (AGHD). Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced that they met the primary endpoint in their Phase 2b Kinect 2 trial of NBI-98854 in patients with tardive dyskinesia. They intend to submit […]

Read more

Offering news for AEZS APPA CSII NWBO +CYTR FOLD news

Nov 21, 2013 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.05) priced their public offering of 13.1 million units, with each unit consisting of one common share and one whole warrant to purchase one common share, at a purchase price of US$1.15 per unit. Net proceeds are expected to be approximately $13.7 million. CytRx Corporation (NASDAQ: CYTR $2.15) announced initiation of […]

Read more

AEZS file NDA. IMGN fail Phase 2 trial. ECYT decision due Dec-Jan. ADHD data due Dec. KERX positive data + updates for STEM SGEN PTLA ISIS INSM ZGNX ITMN

Nov 06, 2013 No Comments

Aeterna Zentaris Inc. (NASDAQ: AEZS $1.39) announced that it has submitted a NDA for AEZS-130 for adult growth hormone deficiency (“AGHD”). ImmunoGen, Inc. (Nasdaq: IMGN $13.41) announced that it will discontinue their Phase 2 trail of IMGN901 for SCLC, following the recommendation from the Data Monitoring Committee (DMC) due to a higher rate of infection and […]

Read more